A Comparison of Rimegepant Orally Disintegrating Tablet (Nurtec ODT) to Rizatriptan Benzoate Orally Disintegrating Tablet (Maxalt MLT-ODT) in Adult Patients Presenting to the ED With Migraine Headache: Randomized, Double-Blind, Clinical Trial

Rimegepant (Nurtec) is an orally administered small molecule CGRP receptor antagonist with efficacy in the acute treatment of migraine. Rizatriptan benzoate (MAXALT), is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist. Rizatriptan binds with high affinity to human cloned 5-HT1B and 5-HT1D receptors which leads to activation of these receptors results in cranial vessel constriction, inhibition of neuropeptide release and reduced transmission in trigeminal pain pathways with resultant relieve of the headache.
Teh investigators hypothesize that the administration of Rimegepant ODT would provide better analgesic efficacy than Rizatriptan ODT with respect to analgesic efficacy at 60 min and 120 minutes in ED patients with acute headache.
This is a prospective, randomized, double-blind superiority trial evaluating and comparing analgesic efficacy and safety of Rimegepant ODT 75 mg to Rizatriptan ODT 10 mg in adult patients presenting to the Emergency Department of Maimonides Medical Center with acute migraine headache.

Start Date01 Sep 2024

Sponsor / Collaborator

Maimonides Medical Center

IRCT20230913059428N1

/ SuspendedPhase 3IIT

A clinical trial of sublingual Rizatriptan versus oral Betahistin in acute phase treatment of vertigo in patients suffering from vestibular migraine

Start Date23 Oct 2023

Sponsor / Collaborator

Tabriz University of Medical Sciences

100 Clinical Results associated with Rizatriptan Benzoate

100 Translational Medicine associated with Rizatriptan Benzoate

100 Patents (Medical) associated with Rizatriptan Benzoate

1,448

Literatures (Medical) associated with Rizatriptan Benzoate

01 Sep 2026·CONTRACEPTION

Stroke in combined hormonal contraceptive users treated with triptans

Article

Author: Andersen, Klaus Kaae ; Letnar, Gasper ; Olsen, Tom Skyhøj

OBJECTIVES:

The extent of triptan use among users of combined hormonal contraceptives (CHC) is unknown. Likewise, it is unclear whether triptan use influences the risk of stroke in CHC users. In a Danish population of CHC users, we examined the prevalence of triptan use and assessed its impact on stroke risk.

STUDY DESIGN:

In this historical cohort study based on registries covering the Danish female population aged 18-49 years 2004-2021 we investigated incidence rate ratios (IRR) and incidence rate differences (IRD) of ischemic (IS) and hemorrhagic (ICH) stroke in users of CHCs who had been prescribed triptans compared with those without triptan use. Poisson regression models adjusting for age, ethnicity, education, calendar year and risk factors were applied.

RESULTS:

Among 1711,757 women, 982,962 (57%) were CHC users, contributing 4446,000 person-years of CHC use. Of these, 98,399 (10%) had used triptans, contributing 325,000 person-years. CHC users with triptan prescriptions had an increased risk of IS compared to users without prescriptions (IRR 1.60; 95% CI 1.33,1.92); IRD range by age group 2-42/100,000 person-years). Stroke risk was independent of triptan prescription frequency and ethinylestradiol dose. Compared with women who use neither CHCs, other hormonal contraceptives, nor triptans, CHC users with triptan prescriptions had an increased risk of IS (IRR 2.61; 95% CI: 2.21-3.08). Risk was not increased for ICH.

CONCLUSIONS:

Among approximately one million Danish CHC users, 10% had been prescribed triptans. In this population the risk of IS was increased 1.60-fold compared with those without triptan use. Triptan use constitutes a risk factor for IS in CHC users. Although the absolute risk is generally low, it is highest among the oldest users.

IMPLICATIONS:

Among approximately one million Danish CHC users, 10% had been prescribed triptans, and in this group the risk of ischemic stroke was 1.60 times higher. Among CHC users with migraine, triptan use should be regarded as a risk factor for ischemic stroke and taken into account when considering CHCs as a contraceptive option.

01 Sep 2026·JACC. Case reports

Left Main Spontaneous Coronary Artery Dissection in a Young Woman With Migraine and Triptan Use

Article

Author: Kyhan, Mohammad Eshaq ; Kalra, Aarushi ; George, Zachary

BACKGROUND:

Spontaneous coronary artery dissection (SCAD) results from intramural hematoma formation within the coronary arterial wall. It predominantly affects young women and is associated with physical or emotional stress, hormonal influences, and vasoactive medications.

CASE SUMMARY:

A 33-year-old woman presented to the emergency department with acute chest pain 1 hour after taking 100 mg of sumatriptan. Electrocardiography demonstrated ST-segment elevation in aVL and diffuse ST-segment depressions. Coronary angiography revealed left main SCAD with thrombosis, treated with thrombectomy and stenting. She developed cardiogenic shock requiring prolonged mechanical circulatory support. Hospitalization course was also complicated by an ischemic stroke and spinal cord infarction. She was stabilized and discharged to rehabilitation.

DISCUSSION:

Triptans are associated with coronary vasospasm; their potential role in precipitating SCAD in susceptible individuals remains poorly characterized.

TAKE-HOME MESSAGE:

SCAD may occur in patients with migraines even without traditional cardiovascular risk factors and especially after exposure to triptans.

01 Sep 2026·ARQUIVOS DE NEURO-PSIQUIATRIA

Delayed diagnosis of cluster headache in Portugal

Article

Author: Moreira, Stefanie ; Alves, Ivânia ; Bonifácio, Gonçalo V. ; Costa, Andreia ; Cabral, Mariana ; Pinto, Sofia Marinho ; Andrade, Carlos ; Barreto, Beatriz ; Almeida, Pedro ; Silva, Lénia ; Rocha, Ana Luísa ; Costa, Aurora ; Varanda, Sara ; Castro, Rita ; Dias, Rafael ; Pinto, Madalena ; Millner, Tiago

Abstract:

Cluster headache (CH) has well-defined diagnostic criteria, but its diagnostic delay (DD) remains substantial, averaging 3.6 to 9 years, leading to inappropriate treatments and significant psychosocial and socioeconomic burdens.To identify demographic and clinical factors associated with DD in CH to promote earlier diagnosis.A multicenter cross-sectional study recruited 64 patients with episodic or chronic CH from 6 Portuguese neurology centers. Participants completed an online questionnaire covering demographics, clinical features, prior consultations, diagnoses, and treatments. Diagnostic delay was defined as the time from symptom onset to formal diagnosis. Correlation tests and multiple linear regression were performed to identify predictors of DD.The mean DD was of 6.4 ± 8.3 (range: 0–39) years, with 46.9% experiencing delays > 4 years. No sex differences were observed. Younger age at onset (ρ = –0.45; p < 0.001); attack onset between midnight and 3 am (p = 0.029), and eyelid edema (p = 0.001) were associated with shorter DD. The number of pain episodes before neurology consultation strongly correlated with DD (ρ = 0.92; p < 0.001), underscoring the impact of referral delays. Most patients (59.4%) received alternative diagnoses, mainly migraine and sinusitis. Prior triptan (p = 0.037) and topiramate use (p = 0.012) were linked to longer DD. Multivariate models highlighted age at onset and clinical features as primary predictors, explaining nearly 60% of variance.Diagnostic delay in CH remains considerable in Portugal. Increasing awareness among primary care physicians and non-neurologist specialists is crucial to reduce DD and inappropriate treatments. Further research should clarify the role of educational level and support targeted interventions for timely recognition.

News (Medical) associated with Rizatriptan Benzoate

04 Jun 2026

·www.biospace.com

Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new SYMBRAVO ® data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting being held from June 4-7 in Orlando, FL. Details of the presentations are as follows: Title: SYMBRAVO (MoSEIC™ meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Return to Function Endpoint Analysis from MOMENTUM Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Richard Lipton, MD, Professor of Neurology and Director of the Montefiore Headache Center, Albert Einstein College of Medicine, NY Poster Number: T19 Title: Comparative Efficacy of SYMBRAVO vs. Gepants for Acute Treatment of Migraine: A Network Meta-Analysis Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Stephanis Nahas, MD, MSEd, Professor of Neurology, Thomas Jefferson University, PA Poster Number: T24 Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Treatment of Migraine: Sustained Pain Relief and Pain Freedom Among 2-Hour Responders in the Phase 3 MOMENTUM and MOVEMENT Trials Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Chia-Chun Chiang, MD, Assistant Professor of Neurology at the Mayo Clinic, Rochester, MN Poster Number: T30 Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Safety Endpoint Analysis of INTERCEPT and MOMENTUM Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Fred Cohen, MD, Assistance Clinical Professor of Neurology, Icahn School of Medicine, Mount Sinai, NY Poster Number: T33 About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at and follow us on LinkedIn and X . Forward Looking Statements Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI ® , AUVELITY ® , and SYMBRAVO ® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investors: Ashley Dong Senior Director, Investor Relations (929) 687-1614 adong@axsome.com Media: Darren Opland Senior Director, Corporate Communications (929) 837-1065 dopland@axsome.com

Phase 3NDA

04 Jun 2026

·axsometherapeuticsinc.gcs-web.com

Axsome Therapeutics Presents New SYMBRAVO® Data at the American Headache Society (AHS) 68th Annual Scientific Meeting

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new SYMBRAVO® data at the American Headache Society (AHS) 68th Annual Scientific Meeting being held from June 4-7 in Orlando, FL. Details of the presentations are as follows: Title: SYMBRAVO (MoSEIC™ meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Return to Function Endpoint Analysis from MOMENTUM Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Richard Lipton, MD, Professor of Neurology and Director of the Montefiore Headache Center, Albert Einstein College of Medicine, NY Poster Number: T19 Title: Comparative Efficacy of SYMBRAVO vs. Gepants for Acute Treatment of Migraine: A Network Meta-Analysis Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Stephanis Nahas, MD, MSEd, Professor of Neurology, Thomas Jefferson University, PA Poster Number: T24 Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Treatment of Migraine: Sustained Pain Relief and Pain Freedom Among 2-Hour Responders in the Phase 3 MOMENTUM and MOVEMENT Trials Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Chia-Chun Chiang, MD, Assistant Professor of Neurology at the Mayo Clinic, Rochester, MN Poster Number: T30 Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Safety Endpoint Analysis of INTERCEPT and MOMENTUM Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Fred Cohen, MD, Assistance Clinical Professor of Neurology, Icahn School of Medicine, Mount Sinai, NY Poster Number: T33 About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X. Forward Looking Statements Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investors: Ashley Dong Senior Director, Investor Relations (929) 687-1614 adong@axsome.com Media: Darren Opland Senior Director, Corporate Communications (929) 837-1065 dopland@axsome.com

Phase 3NDA

28 Oct 2025

·www.businesswire.com

Wisp Launches Comprehensive Migraine Care Vertical, Innovating Category with First-Ever, Asynchronous Care

NEW YORK--(BUSINESS WIRE)--Wisp, the largest pure play women's telehealth company in the U.S., today announced the launch of a dedicated migraine care vertical, consisting of online consults, prescription medications, and ongoing follow-up to help patients manage and prevent migraines. Wisp’s migraine specialists, certified by the National Headache Foundation, create customized treatment plans, expanding access to affordable, convenient care for patients wherever they are. Migraines affect one in five women — occurring nearly three times as often in women as in men — yet timely access to care remains a major barrier. On average, patients wait 34 days to see a neurologist, and in some cases, more than 90 days. Wisp’s new offering enables patients to receive care in 72 hours or less. “Migraine care is the natural next step for Wisp,” said Monica Cepak, CEO of Wisp. “Only one in four adults with episodic migraines receive diagnosis and treatment, and our patients continue to ask for treatment options. We’re delivering on our promise, with diagnoses made online, to democratize access to care, breaking down barriers so women can enjoy more pain-free days without the long wait times or high costs.” Wisp’s migraine care program includes: Migraine Consults ($60): Initial consults repeat every 6 weeks until the patient is on a stable dose. Quarterly Check-Ins ($30): Once stabilized, patients check in every 3 months for prescription refills. Prescriptions for Immediate Relief: Imitrex (Sumatriptan), Maxalt (Rizatriptan), Zomig ODT (Zolmitriptan). Anti-Nausea Medications: Zofran ODT (Ondansetron), Reglan (Metoclopramide). Preventive Medications: Topamax (Topiramate), Toprol XL (Metoprolol XL), Elavil (Amitriptyline), Lexapro (Escitalopram), Paxil (Paroxetine), Effexor ER (Venlafaxine ER). Patients begin with a $60 consult, complete a short intake form, and upload brief videos to help diagnose and assess eligibility. From there, a licensed provider reviews their medical history and intake to recommend a treatment plan, which may include immediate relief, anti-nausea, or preventive medications. Prescriptions are then sent the same day to the patient’s local pharmacy, with no insurance needed. “Migraines can be incredibly disruptive, but they are also very manageable with the right treatment plan,” said Dr. Jennifer Peña, Chief Medical Officer at Wisp. “Our approach provides patients with timely access to providers, tailored treatment options, and ongoing support so they feel empowered to take control of their health.” This launch follows Wisp’s recent expansion of its weight care vertical, furthering the company’s mission to provide affordable and accessible care for women across all life stages. From sexual and reproductive health to at-home diagnostics, fertility, menopause, to weight care and now migraine management, Wisp is continuing to build the most comprehensive platform designed for the unique needs of women. About Wisp: Wisp is the largest pure play women’s telehealth provider in the U.S., serving more than 1.5 million patients nationwide. Offering discreet, online care and a comprehensive range of first-to-market products, Wisp addresses women’s health needs across every stage of life—from birth control to fertility, menopause, STI testing, and more. Recognized by Fast Company as one of the Most Innovative Companies of 2023 and by Inc. as Best in Business 2024, Wisp is majority-owned by WELL Health Technologies Corp. Visit hellowisp.com or follow @hellowisp on social media.

100 Deals associated with Rizatriptan Benzoate

External Link

KEGG	Wiki	ATC	Drug Bank
D00675	Rizatriptan Benzoate	N02CC04	DB00953

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Migraine Disorders	Mexico	Merck Sharp & Dohme Corp.	21 Jan 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Migraine With Aura	Phase 3	United States	Merck Sharp & Dohme Corp.	01 Apr 2007
Migraine Without Aura	Phase 3	United States	Merck Sharp & Dohme Corp.	01 Apr 2007
Acute migraine	Phase 3	-	Organon & Co.	01 Mar 1995
Post-Traumatic Headache	Clinical	United States	Merck Sharp & Dohme Corp.	01 Feb 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAN2026	Not Applicable	Migraine Disorders	201	Rizatriptan 10 mg	upxmffvxma(avbzowryel) = Adverse events were mild and did not lead to discontinuation. No serious adverse events occurred rtrreucdto (axnrkidsgv )	Positive	25 Apr 2026
				Zolmitriptan 2.5 mg
FDA Manual	Not Applicable	Migraine Disorders	-	Rizatriptan 10 mg (Studies 1)	cybqciynja(ltqnujjhjz) = twdlsfevqy itqhcopseh (bwddqnlypy )	Positive	14 Apr 2023
				Placebo (Studies 1)	cybqciynja(ltqnujjhjz) = ilblmycpdm itqhcopseh (bwddqnlypy )
NCT00360282 (Pubmed \| Cochrane Database Syst Rev)	Not Applicable	Migraine Disorders	133	Triptans	yldoocqivi(asbusfaego): risk ratio = 0.84 (95% CI, 0.66 - 1.07)	-	12 Apr 2023
				Placebo
NCT02447991 (CTgov)	Phase 2/3	Vertigo \| Dizziness \| Migraine Disorders	223	Placebo (Placebo)	icreqzkmnp = civpjuzpex dgodqbrynf (ykhfcwyuqd, cuucrgyokp - bzffaialla) View more	-	04 Nov 2021
				Rizatriptan (Rizatriptan)	icreqzkmnp = qdsvjhsyyd dgodqbrynf (ykhfcwyuqd, urrkzqmqzf - dkbykzgier) View more
NCT01086358 (CTgov)	Phase 4	Migraine Disorders	60	almotriptan+eletriptan+Treximet+rizatriptan+sumatriptan+zolmitriptan+triptan (Arm 1 - Triptan)	zcqkufsiwg(kunleqnehe) = sweinkcapb mddfemqxkh (szxlysldtk, ywamhmyynw - rqpzqkyzoi) View more	-	01 May 2018
				Naproxen Sodium (Treximet)+Sumatriptan (Arm 2 - Sumatriptan/Naproxen Sodium (Treximet) Arm)	zcqkufsiwg(kunleqnehe) = kimwpppiwu mddfemqxkh (szxlysldtk, neofxuconx - uoysnsnjwu) View more
NCT00360282 (CTgov)	Not Applicable	Migraine Disorders	36	Rizatriptan (Rizatriptan Visit)	mvqbnowdgs(tiuasyzdqg) = dlkghgsjlo sdtkmrctmv (bumwrncznr, gqxmghlzwl - plmtpoztba) View more	-	08 Dec 2014
				Placebo (Placebo Visit)	mvqbnowdgs(tiuasyzdqg) = fsdvotdqpe sdtkmrctmv (bumwrncznr, irewgxvlzb - uhrlsttqhu) View more
NCT01004263 (Pubmed \| Headache)	Phase 3	Migraine Disorders	674	Rizatriptan 5mg	kstqjacogv(gnqydgashf) = tabvpibkyk rckgrfhtdr (fhzbhwwyrk ) View more	-	01 Jan 2013
				Rizatriptan 10mg	kstqjacogv(gnqydgashf) = ldlyyenvjl rckgrfhtdr (fhzbhwwyrk ) View more
NCT01001234 (CTgov)	Phase 3	Acute migraine	1,382	Rizatriptan (Rizatriptan)	cxnsbzbygc = ykomaueiin rlkbzjdplh (wwdgllzkgz, xquwyertxq - mkwmkyvpdo) View more	-	08 May 2012
				placebo (Placebo)	cxnsbzbygc = mjwkkrcccp rlkbzjdplh (wwdgllzkgz, bzxgfuuqmq - liweabxnkm) View more
NCT01004263 (CTgov)	Phase 3	Migraine Disorders \| Migraine With Aura \| Acute migraine	674	rizatriptan benzoate	xdmagyrzeo = esyvzzoivu wcpyjhcdoi (wnejfennfc, lxtuxzmvpc - ufkmgpksdl) View more	-	04 May 2012
NCT00604812 (Pubmed \| Headache)	Phase 1	Migraine Disorders	-	Rizatriptan ODT 5mg	rsbdcjyzui(kkllbcdrkz) = xfthiihudu eooihnqyoh (edkdnlvrqz, 48.60 - 66.09) View more	-	01 Apr 2012
				Rizatriptan 10mg ODT	rsbdcjyzui(kkllbcdrkz) = ejjakapiob eooihnqyoh (edkdnlvrqz, 68.93 - 89.38) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis